Providing immediate Covid-19 protection for frontline healthcare workers.

Video Interview

Aegros is an Australian Bio-Pharma company that is about to completely disrupt the global Plasma market. Aegros vision is to develop & deliver the best Hyperimmunes to protect against existing and emerging diseases.

Aegros will achieve this by integrating its multi patent pending HaemaFrac™ technology with existing processes to deliver safe & affordable therapeutic plasma products.

Aegros’s first product is a Covid-19 hyperimmune called Covimmune which can offer immediate passive immunity for frontline health workers and those unable to take vaccines.

Interview timestamps

  • Introduction & why Pulse Markets like Aegros 0:01

  • Aegros: same products as CSL at a fraction of cost & more efficiently 1:15

  • How Covimmune provides immediate protection from Covid-19 2:00

  • Why so many people worldwide can’t take vaccines 3:00

  • How Covimmune quickly adapts to Covid-19 mutations 3:30

  • Why Covimmune will be successful 4:00

  • The core of the technology- high small volumes & high recoveries 5:05

  • Why the NBA & other authorities want this 5:25

  • Aegros advantage over existing providers 5:50

  • How Covimmune is the wedge to be a global Fractionator giant – $19B global market 6:05

  • Aegros using their HaemaFrac technology to be Australia’s 2nd fractionator 7:00

  • Why Aegros can do this better than CSL & others 7:45

  • How Aegros can ensure Australia has guarantee of proteins supply 8:20

  • Fractionator technology is 75 years old, this is the first change to that 8:35

  • A 30 year journey to get to this point, trials etc 9:05

  • Timeline to issue of TGA license 9:35

  • Significance of TGA license 10:00

  • 3 different revenue streams & their timelines 10:30

    • Therapeutic Products: Covimmune, then IVIG & Albumin 10:45

    • License the Aegros process globally 11:10

    • Manufacture of Membranes for use in machines using the process 12:05

  • Understanding the Aegros model & patient involvement (B2G)

  • Why the Clinical Trial will only be 42 days 13:40

    • Near-term milestones 14:40

    • TGA approval ~end Sept 2021

    • GMP approval ~end Sept 2021

    • Complete Clinical trials ~Dec 2022

    • First orders from NBA (National Blood Authority)

    • Potential revenue Q2 2022

    • Sign replication deals globally

    • IPO Q 2 2022

  • Comparable market caps 15:40

  • Use of funds in this raise 16:50

  • Disclaimer 17:50


Important Notice

Please refer disclaimer at end of interview. This information must not be taken as financial advice please consult a financial professional before making any investment decision. Pulse Markets takes no responsibility for any of the claims in this interview. This company may not be suitable for your investment needs.


Enter your details to invest in Aegros…